August 2, 2024 10:29 AM EDT
People
Startups

PARP biotech backed by more than five phar­mas clos­es af­ter nine years

Kyle LaHucik

Senior Reporter

Ri­bon Ther­a­peu­tics has shut­tered af­ter nine years, and one year af­ter end­ing its pre­clin­i­cal re­search to fo­cus on two ear­ly-stage PARP pro­grams …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

In sur­prise, study sug­gests Covid mR­NA vac­cines may boost can­cer im­munother­a­py ef­fi­ca­cy

Mer­ck­'s Eli­av Barr on sub­cu­ta­neous Keytru­da, Sum­mit and deal shop­ping

FDA tells on­col­o­gy com­pa­nies how to run mul­ti-re­gion­al can­cer tri­als with a US ap­proval in mind

Boehringer plans NDA fil­ing for pul­monary fi­bro­sis drug fol­low­ing Phase 3 da­ta

Pfiz­er tees up Phase 3 test in weight man­age­ment — but in an un­ex­pect­ed area

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times